|
Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). |
|
|
Travel, Accommodations, Expenses - Eisai |
|
|
No Relationships to Disclose |
|
Francisco José Bautista Sirvent |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bayer; Clinigen Group |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Clinigen Group |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Loxo |
|
|
|
|
|
Consulting or Advisory Role - Bayer; Clinigen Group; Isofol Medical; Lilly; Novartis; Pfizer |
Research Funding - Amgen (Inst); Eisai (Inst); Janssen-Cilag (Inst); Loxo (Inst) |
|
|
Honoraria - Amgen; Celgene; Eisai; Pfizer; Roche |
Consulting or Advisory Role - Amgen; Celgene; Eisai; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
|
|
|
|
|
|
|
|
Research Funding - Eisai (Inst) |
|
|
No Relationships to Disclose |